思路迪醫藥股份：二零二四年中期報告.pdf

1、2024INTERIM REPORT中期報告思路迪医药股份有限公司Contents目錄2Definitions釋義7Corporate Information公司資料10Financial Summary財務概要14Business Highlights業務摘要17Management Discussion and Analysis管理層討論及分析44Other Information其他資料63Independent Review Report獨立審閱報告65Interim Condensed Consolidated Statement of Comprehensive Income中期簡

2、明綜合損益及 其他全面收益表66Interim Condensed Consolidated Statement of Financial Position中期簡明綜合財務狀況表68Interim Condensed Consolidated Statement of Changes in Equity中期簡明綜合權益變動表69Interim Condensed Consolidated Statement of Cash Flows中期簡明綜合現金流量表72Notes to Interim Condensed Consolidated Financial Information中期簡明綜合財

3、務資料附註23D Medicines Inc.Interim Report 2024Definitions釋義“恩維達”envafolimab(brand name:ENWEIDA,恩維達),a subcutaneously-injectable PD-L1 inhibitor for the treatment of tumor-agnostic indication恩維達恩沃利單抗（品牌名：恩維達）是一款用於治療泛瘤種的皮下注射PD-L1抑制劑“AML”acute myeloid leukemia,a type of cancer that progresses rapidly and a

4、ggressively,and affects the bone marrow and bloodAML急性髓性白血病，一種發病快且侵襲性強的癌症，會影響骨髓和血液“Articles of Association”the amended and restated articles of association of the Company adopted on June 28,2024組織章程細則本公司於2024年6月28日採納之經修訂及重列組織章程細則“Audit Committee”the audit committee of the Board審核委員會董事會審核委員會“BLA”biol

5、ogic license applicationBLA生物製品許可證申請“Board of Directors”or “Board”the board of Directors董事會董事會“CD3”cluster of differentiation 3,a protein complex(enzyme)and T-cell co-receptor that is involved in activating both the cytotoxic T-cell and T helper cellsCD3分化簇3，一種蛋白質複合物（酶）和T細胞共受體，涉及激活細胞毒性T細胞和輔助性T細胞“CDE

6、”center for drug evaluation of the NMPACDE國家藥品監督管理局藥品審評中心“CG Code”the“Corporate Governance Code”as contained in Appendix C1 to the Listing Rules 企業管治守則 上市規則 附錄C1所載的 企業管治守則“China”or“PRC”the Peoples Republic of China,which,for the purpose of this interim report and for geographical reference only,excl